Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 14, 2010	4 Stocks We're Buying As part of our "11 O'Clock Stock" series, we like Domino's Pizza, IBM, Teva Pharmaceuticals, and Take-Two Interactive.
The Motley Fool September 15, 2010 Bryan Hinmon	Today's Buy Opportunity: Landstar Any upside from a recovering domestic economy or continued shift into brokered trucking could send Landstar's shares into overdrive.
The Motley Fool September 26, 2009 Rick Aristotle Munarriz	The Fool's Look Ahead Accenture, Cal-Maine Foods, Worthington Industries, and Nike are among others that will decorate the week that lies ahead.
The Motley Fool September 14, 2010 Nate Weisshaar	Today's Buy Opportunity: CGG Veritas We probe beneath the surface of this seismic mapper.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool September 30, 2010 Jacob Roche	Cal-Maine Foods Fries Up a Tasty Quarter Like a poached egg -- soft, but delicious.
The Motley Fool April 15, 2005 Stephen D. Simpson	Landstar Gets a Gold Star This trucking company doesn't have tangible assets, but it continues to haul in good profits. Investors, take note.
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.
The Motley Fool September 28, 2009 Brian Orelli	The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool June 25, 2010 Brian Orelli	The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error.
The Motley Fool March 28, 2009 Rick Aristotle Munarriz	The Fool's Look Ahead Eggs, earnings, and education will decorate the week that lies ahead.
The Motley Fool September 19, 2010	Why We're Buying Apple Apple has the following four factors in its favor that indicate it still has a lot of growth in it.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool December 27, 2008 Rick Aristotle Munarriz	The Fool's Look Ahead Who's reporting this week: Cal-Maine Foods... Rick's Cabaret...
The Motley Fool November 10, 2008 David Lee Smith	Don't Miss This Seismic Sparkler Paris-based seismic player CGGVeritas looks poised to pop.
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool June 20, 2006 Shruti Basavaraj	Doubles Are Better Than Home Runs Loads of investors think they want to find the next home run stock. These potential 10-baggers keep many of us in the investing game. While it's good to aim for the fences, investors should be content with the doubles.
The Motley Fool March 20, 2009 Brian Orelli	No More Tears, Far More Fears? China's Food and Drug Administration said that it's investigating products made by our beloved Johnson & Johnson, after a U.S. group reported that there may be carcinogens in J&J's baby shampoo.
The Motley Fool December 1, 2010 Brian Orelli	We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell.
The Motley Fool September 11, 2010 Anand Chokkavelu	How Much of a Bargain Is Johnson & Johnson Stock Right Now? Let's take a look to see how cheap shares of Johnson & Johnson are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis.
The Motley Fool May 12, 2010 Nick Kapur	J&J: A Winner on Both Sides of the Ball (Fool TV) If you're looking to build a dynasty in your portfolio, you'd be hard-pressed to find a better-balanced outfit than veteran Johnson & Johnson. The consumer products giant is discussed in this video.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool March 14, 2011 Bryan Hinmon	Rising Star Buy: Landstar System Getting behind the wheel and buying shares.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool July 23, 2010	The 4 Most Important Financial Metrics You're busy. You've got things to do that don't involve poring through financial statements until the cows come home.
The Motley Fool December 18, 2008 Jim Mueller	The Best Stocks for 2009 How did the Best Stocks of 2008 do? And which stocks might best help your portfolio's recovery next year?
The Motley Fool July 26, 2005 Rich Smith	J&J: One Pricey Stock This giant of the health-care world reported its second quarter 2005 earnings last week but, by all appearances, failed to impress Wall Street. Johnson & Johnson's become very big, very pricey.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool August 3, 2005 Steven Mallas	JNJ: One to Monitor Johnson & Johnson might not exactly be a bargain, but it should always be on your stock watch list.
The Motley Fool September 13, 2010 Nick Kapur	Today's Buy Opportunity: Cal-Maine Foods If market outperformance is what gets your motor humming, check out Cal-Maine, a family-owned business that also happens to be the nation's largest producer, packager, and distributor of shelled eggs in the U.S.
The Motley Fool August 24, 2010 Matt Koppenheffer	How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale?
The Motley Fool November 16, 2007 Toby Shute	Oh, Say Can You CGG? While there's nothing wrong with the numbers that leading seismic company CGG Veritas reported this quarter, investors disappointment may stem from the greater surge experienced by competitors.
The Motley Fool August 3, 2004 W.D. Crotty	Investing in the Golden Egg Cal-Maine Foods, the largest egg processor in the U.S. decided it was time to repurchase its own shares now that the stock sells fro 4.6 times trailing earnings.
The Motley Fool May 16, 2006 Rich Smith	Symantec Still Flat An earnings beat isn't all it's cracked up to be. Symantec is continuing to post ugly numbers, and may do so until it has fully digested Veritas. Investors, take note.
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool November 9, 2006 Shruti Basavaraj	The Best Blue Chip for 2007: Johnson & Johnson If you're out looking for the best blue chip money can buy, consider Johnson & Johnson. The stock combines strong growth opportunities with stability. It's the ideal stock to build the core of your portfolio.
The Motley Fool February 26, 2007 Tim Beyers	Fool on the Street: Healthy Heinz Apparently, selling health is healthy for business. But organic innovation isn't the most important factor in going global. Investors, take note.